Press Releases Kaleido Biosciences, Inc.

Equities

KLDO

US4833471000

Delayed OTC Markets Other stock markets 14:33:35 08/05/2024 BST			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	+9,900.00%

2022	Kaleido Biosciences, Inc.(NasdaqGS:KLDO) dropped from S&P Global BMI Index	CI
2022	Kaleido Biosciences, Inc.(NasdaqGS:KLDO) dropped from S&P TMI Index	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CapitalGainsReport: Must See Healthcare Stocks Under $1 (WHSI, KLDO, AGRX, PTE, AKBA)	14/04/22	AQ
KALEIDO BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	08/04/22	AQ
KALEIDO BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	01/04/22	AQ
KALEIDO BIOSCIENCES, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	17/03/22	AQ
KALEIDO BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)	09/03/22	AQ
KALEIDO BIOSCIENCES, INC. : Other Events (form 8-K)	28/01/22	AQ
Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn’s and Colitis Congress	21/01/22	GL
Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn’s and Colitis Congress	21/01/22	GL
Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potential of Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic Conditions	06/12/21	GL
Kaleido Biosciences to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference	15/11/21	GL
Kaleido Biosciences to Appoint Dr. Alison Long as Chief Medical Officer	10/11/21	GL
KALEIDO BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	01/11/21	AQ
Press Release issued by Kaleido Biosciences, Inc., dated November 1, 2021, furnished herewith - Form 8-K	01/11/21	PU
Kaleido Biosciences Reports Third Quarter 2021 Financial Results	01/11/21	AQ
Kaleido Biosciences : to Participate in the Jefferies Virtual Next Generation IBD Therapeutics Summit	12/10/21	AQ
KALEIDO BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	05/10/21	AQ
Kaleido Biosciences : Announces New Clinical and Preclinical Data Supporting Advancement of KB295 to a Phase 2 Clinical Study in Mild-to-Moderate Ulcerative Colitis	05/10/21	AQ
Kaleido Biosciences to Host Virtual R&D Presentation to Discuss Clinical Data and Pipeline Advancement on October 5, 2021	29/09/21	GL
KALEIDO BIOSCIENCES, INC. : Other Events (form 8-K)	03/09/21	AQ
Kaleido Biosciences to Participate in the Morgan Stanley 19th Annual Virtual Global Healthcare Conference	02/09/21	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Kaleido Biosciences, Inc.

Equities

KLDO

US4833471000

Press Releases

Filters